At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 384 enrolled
Drug / intervention
Buserelin and Pregnyl +3 moredrug
Likely dose
Buserelin and Pregnyl 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Randomised Study to Evaluate the Effect of Triggering Ovulation With GnRHa (Buserelin) and Low Dose hCG (Pregnyl) as Compared to the Use of Conventional Doses of hCG (Pregnyl)
In Brief
A Phase 4 clinical trial evaluating Buserelin and Pregnyl and Pregnyl for OHSS (Ovarian Hyperstimulation). Completed, enrolled 384 participants across 1 site.
Detailed Summary
The purpose of this study is to possibly further improve the clinical outcome and explore the incidence of OHSS in patients, who have final oocyte maturation with GnRHa (Buserelin) in GnRH antagonist IVF/ICSI cycles
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOHSS (Ovarian Hyperstimulation)
CountriesDenmark
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartJan 2009
Primary CompletionDec 2011
TodayJul 2026
First PostedMar 3, 2008
Enrollment StartJan 1, 2009
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 18.3 years ago
Interventions
Buserelin and Pregnyldrug
Subcutaneous injection 0.5 mg and 1500 IU
Pregnyldrug
Subcutaneous injection 5000 IU
Buserelin and Pregnyldrug
Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
Pregnyldrug
Subcutaneous injection 5000 IU